Indolone IRAK4 Inhibitors and PROTAC Degraders Against Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule IRAK4 kinase inhibitors fail to achieve ideal therapeutic effects due to target protein mutation-induced resistance and have insufficient activity, while current PROTAC drugs targeting IRAK4 are lacking in clinical research in China.
Innovation Solution
Development of a small molecule indolone derivative with IRAK4 inhibitory activity and an IRAK4-targeted PROTAC molecule that exhibits high selectivity, improved physical and chemical properties, enhanced pharmacokinetics, reduced toxicity, and resistance to drug resistance, formulated into pharmaceutical compositions for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule IRAK4 kinase inhibitors are used, then IRAK4 kinase activity is inhibited, but therapeutic effect is insufficient and target protein mutation-induced resistance occurs
Solution Approach 1:
The patent extracts and eliminates the harmful scaffold activity of IRAK4 by using PROTAC technology to selectively degrade the protein, rather than merely inhibiting its kinase activity. This allows the inhibitory function to be separated from the problematic scaffold function that leads to resistance.
Solution Approach 2:
The patent changes the mechanism of action from kinetic inhibition to protein degradation. By altering the fundamental parameter of how IRAK4 is targeted (from binding to destruction), the system overcomes mutation-induced resistance while maintaining therapeutic efficacy.
2Reliability
If traditional small molecule IRAK4 inhibitors are used, then kinase activity is inhibited, but physical and chemical properties and pharmacokinetics are insufficient
Solution Approach 1:
The patent employs a composite PROTAC molecule structure combining an IRAK4 inhibitor moiety with an E3 ubiquitin ligase ligand through a linker. This composite design integrates multiple functions (inhibition and degradation targeting) into a single molecular system with improved stability and pharmacokinetic properties.
3Reliability
If traditional small molecule IRAK4 inhibitors are used, then kinase activity is inhibited, but toxicity and side effects increase
Solution Approach 1:
The patent extracts the harmful scaffold activity from IRAK4 targeting by using PROTAC-mediated degradation. This selective degradation approach eliminates the protein entirely rather than merely inhibiting its activity, reducing off-target effects and toxicity while maintaining specific therapeutic activity.
4Reliability
If PROTAC technology is used to target IRAK4, then both kinase and scaffold activities are inhibited through protein degradation, but no PROTAC drug targeting IRAK4 has entered clinical research phase in China
Solution Approach 1:
The patent performs preliminary design and optimization of the PROTAC molecule structure in vitro, establishing the foundational compound and methodology before advancing to clinical trials. This preliminary development phase creates the necessary data and validation required for subsequent clinical research phases.
Data Source
AI summary
The present application relates to an indolone derivative having an IRAK4 inhibitory activity as represented by formula (I), a preparation method therefor and the use thereof, and further relates to a compound capable of inhibiting and degrading the IRAK4 protein and a pharmaceutical composition comprising the indolone derivative or the compound capable of inhibiting and degrading the IRAK4 protein.